Ann: Initial Director's Interest Notice, page-17

Considering that by most calculations, our cash burn is now equivalent to the quarterly costs of supporting the vax division ($3m/Q), a lot of people just wish we could dump admedus vaccines and suddenly be profitable, considering profitability with $24m annual revenues (a very conservative estimate at this point) would give us a valuation of 4 or 5x what we have currently.

I mean, I can see where they're coming from, this journey to profitability has been a long and painful one, but there's untold value in admedus vaccines, and I don't think spinning it off would be the best thing in the long run, unless we got some ludicrous multi-million price for it.
The part of me which revels in instant gratification would still be happy if it happened though, despite my conscious minds opinion on the vaccines value.